Tag-arkiv: national institute of mental health

Depression hos småbørn

ycv0809Et nyt studie har undersøgt om småbørn helt ned til tre års alderen kan have depression. Noget tyder på at det er sandsynligt.
Studiet er det første til at vise at svær depression kan være en kronisk lidelse hos selv meget små børn, i modsætning til den stereotype opfattelse af det altid glade børnehavebarn.

Indtil for ganske nylig har “folk virkelig ikke været særlig opmærksom på depressive lidelser hos børn under 6 år,” udtaler den ledende forfatter til artiklen, professor dr. Joan Luby, børnepsykiater ved Washington University i St. Louis. “Man har ikke troet, at det kunne ske … fordi børn under 6 år var for følelsesmæssigt umodne til at opleve det.”

Læs resten

Ketamine treatment for depression?

Experimental Antidepressant Use

According to a National Institute of Mental Health press release on 7 August 2006, a study of 17 patients led by Dr Carlos Zarate Jr. of the NIMH showed that ketamine significantly improved treatment-resistant major depression within two hours of injection. The improvement lasted up to one week after the single dose. The patients in the study were previously treatment resistant, having tried an average of six other treatments that failed. The importance of these findings was articulated by NIMH director Dr Thomas Insel: “This is the first report of any medication or other treatment that results in such a pronounced, rapid, prolonged response.” The researchers apparently attribute the effect to ketamine being an NMDA receptor antagonist.

The study appears in the Archives of General Psychiatry.

(About Ketamine, see: Wikipedia: Ketamine.) Læs resten

Double-Blind Treatment With Oral Morphine in Treatment-Resistant Obsessive-Compulsive Disorder

For people with obsessive-compulsive disorder (OCD) who have not been helped by standard drug treatments, a weekly dose of oral morphine may ease their symptoms, according to a small pilot study.

|inline

Medtronic Receives Humanitarian Use Device Designation for Treatment of OCD

Den amerikanske virksomhed Medtronic vil snart søge godkendelse hos den amerikanske lægemiddelstyrelse Food and Drug Agency om godkendelse af deres produkt Activa til behandling af behandlingsresistent OCD. Activa benytter Deeb Brain Stimulation terapi og er reversibel modsat for eksempel neurokirurgi.

|inline